AlloVir, Inc. (ALVR)
Stock Price Chart
Key Info
| Market Cap | 2.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 62.67M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 13, 2020 |
| Last Price | $37.38 |
| Previous Close | $37.71 |
| Change ($) | -0.33 |
| Change (%) | -0.88% |
| Day's Open | 37.64 |
| Day's Range | 36.94 - 41.97 |
| Day's Volume | 301,875 |
| 52-Week Range | 18.15 - 45.28 |
More Stats
| Market Cap | 2.34B |
| Enterprise Value | 2.24B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 62.67M |
| Float | 1.75M |
| EPS (basic) | n/a |
| EPS (diluted) | n/a |
| FCF / Share | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | n/a |
| Short Ratio | n/a |
| Short % of Float | n/a |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | n/a |
| PB Ratio | 17.86 |
| Revenue | n/a |
| Operating Income | n/a |
| Net Income | n/a |
| Free Cash Flow | n/a |
| Net Cash | 104.73M |
| Net Cash / Share | 1.67 |
| Gross Margin | n/a |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | n/a |
| ROE | n/a |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 |
|---|---|---|
| Revenue | 0.17 | 1.14 |
| Revenue Growth | -85.46% | - |
| Gross Profit | 0.17 | 1.14 |
| Operating Income | -26.70 | -3.60 |
| Net Income | -23.84 | -2.43 |
| Shares Outstanding | 1.92 | 0.30 |
| Earnings Per Share | -12.44 | -25.07 |
| Operating Cash Flow | -20.16 | 1.94 |
| Capital Expenditures | -0.34 | - |
| Free Cash Flow | -20.49 | 1.94 |
| Cash & Equivalents | 126 | 24.96 |
| Total Debt | 11.76 | - |
| Net Cash / Debt | 114 | 24.96 |
| Assets | 139 | 25.32 |
| Liabilities | 17.80 | 3.74 |
| Book Value | -51.50 | -30.62 |
Company Profile
Company Details
| Full Name | AlloVir, Inc. |
| Country | United States |
| Employees | 20 |
| CEO | David L. Hallal |
Stock Information
| Ticker Symbol | ALVR |
| Stock Exchange | NASDAQ |
| Sector | Technology |
| Industry | Wireless Communications |
| Unique Identifier | NASDAQ: ALVR |
| IPO Date | July 30, 2020 |
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.